A method for generating vapour bubbles in an object comprises introducing a composition into the object, the composition comprising carbon-based nano- or microparticles that can couple with a photon wave of electromagnetic radiation. The method also comprises irradiating said object using electromagnetic radiation. The irradiation thereby is adapted for using a set of carbon-based nano- or microparticles for subsequently forming first vapour bubbles and at least second vapour bubbles using the same carbon-based nano- or microparticles.

The invention relates to an ultrasound contrast agent (UCA) comprising an outer shell and a gas core. The gas core is filled with oxygen, and the outer shell comprises a first surfactant and a second surfactant. The invention also relates to a method of making an oxygen-filled UCA and delivering oxygen to a local area of a subject's body. The method comprises injecting a composition comprising an oxygen-filled UCA of the invention into the subject's body; directing ultrasound radiation to the local area in an intensity sufficient to rupture the UCA.

A method for ascertaining the presence of target-bound microbubbles in the context of ultrasound molecular imaging is taught. This method, referred to herein as dynamic scaling ultrasound molecular imaging, relies upon the time-varying behavior contrast agents within a region expressing a molecular imaging target and that within a reference region. Ultrasound contrast agents compositions that enable use of the method are also taught. The method is useful for the use of ultrasound molecular imaging in diagnosing and monitoring treatment.

Fibrin-targeted microbubbles and their use in ultrasound-based diagnostic and therapeutic applications are disclosed. In particular, the invention relates to the use of fibrin-targeted polymerized shell lipid microbubbles and methods of fabricating and using such fibrin-targeted microbubbles for ultrasound imaging of fibrin deposition in tissue, including adhesions and atherosclerotic plaques. The invention further relates to the use of such fibrin-targeted microbubbles as carriers for drug delivery and in ultrasound-based methods of treatment.

Disclosed are articles, devices and systems providing a semi-rigid acoustic coupling medium for ultrasound diagnostic and treatment techniques. In some aspects, an acoustic coupling article includes a semi-rigid acoustic coupling medium (SACM) able to conform to a receiving body through deformation of the SACM body in order to propagate an acoustic signal within the SACM to and from the receiving body. In some embodiments, the SACM is configured in a shape having one or more attachment portions located at one end of an acoustic interface portion, such that the acoustic interface portion is operable to contact the receiving body to propagate the acoustic signal and the attachment portions are configured to be secured by an acoustic probe device to transmit and receive the propagated acoustic signal.

Provided are photoacoustic imaging contrast agents that include at least one radiation-absorbing component comprising a copper-complexed and/or manganese-complexed chlorin and/or bacteriochlorin and/or a derivative thereof, or a combination thereof. Also provided are methods for using the disclosed photoacoustic imaging contrast agents either singly or in combination for generating an image of a volume, optionally a subject or a body part, cell, tissue, or organ thereof. Further provided are compositions and methods for multiplex photoacoustic imaging of a volume, optionally a subject or a body part, cell, tissue, or organ thereof using photoacoustic imaging contrast agents that include a plurality of the presently disclosed copper-complexed and/or manganese-complexed chlorins and/or bacteriochlorins and/or derivatives thereof simultaneously.

Provided are photoacoustic imaging contrast agents that include at least one radiation-absorbing component comprising a copper-complexed and/or manganese-complexed chlorin and/or bacteriochlorin and/or a derivative thereof, or a combination thereof. Also provided are methods for using the disclosed photoacoustic imaging contrast agents either singly or in combination for generating an image of a volume, optionally a subject or a body part, cell, tissue, or organ thereof. Further provided are compositions and methods for multiplex photoacoustic imaging of a volume, optionally a subject or a body part, cell, tissue, or organ thereof using photoacoustic imaging contrast agents that include a plurality of the presently disclosed copper-complexed and/or manganese-complexed chlorins and/or bacteriochlorins and/or derivatives thereof simultaneously.

A method may include providing a syringe device having (a) a single needle, (b) a first syringe comprising saline with microbubbles, (c) a second syringe comprising a therapeutic compound, and (d) a connector coupling the single needle to the first syringe and to the second syringe. The method may further include guiding the single needle to an injection site of a patient; injecting, with the first syringe, a quantity of saline with microbubbles; confirming a desired position of the single needle, with ultrasound imaging, by identifying the microbubbles in the quantity of saline relative to a tip of the single needle and further relative to one or more anatomical landmarks visible with the ultrasound imaging; and injecting, with the second syringe, the therapeutic compound at the injection site.

An edible negative contrast agent for CT imaging of the gastrointestinal tract intended for oral intake. The contrast agent is a fluid, aqueous foam displaying a CT density contrast value in the range −300 to −800 HU and having a consistency of 7 to 12 cm as measured with Bostwick consistometer. The contrast agent comprises an aqueous continuous liquid phase having a pH of 6.5 to 8.0 and gas bubbles dispersed in the continuous aqueous liquid phase. The aqueous continuous liquid phase comprises a surfactant, the surfactant being a protein, a hydrocolloid acting as foam stabilizer, a buffering agent, and water.

Methods for the diagnosis and treatment of ischemic spinal conditions, degenerative disc disease, back pain and/or other tissue pathologies. Patients with ischemic spine disease can be categorized into subsets that are deemed to have potential to respond to therapy. In particular, therapies are disclosed which involve stimulation of neovascularization so as to increase perfusion of spinal and other anatomies.